Raphael E. Szalat, MD, PhD

Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

I received my medical training at the University of Pierre and Marie Curie, in Paris, France. After Internal Medicine residency, I specialized in Immunology and plasma cell disorders including multiple myeloma and monoclonal gammopathies of clinical significance and became a clinical assistant professor in the department of Immuno-Hematology in Saint-Louis hospital, Paris. I next completed a PhD and post-doc in hematology studying genomics in Multiple Myeloma at the Dana-Farber Cancer Institute, Harvard Medical School in collaboration with La Sorbonne University, Paris and a clinical fellowship in Hematology and Oncology at the Boston University Medical Center. I am currently the multiple myeloma program director and the Stem Cell Transplant director at the Boston University Medical Center. My main interests are to develop myeloma clinical trials and to perform basic and translational research on multiple myeloma and other plasma cell disorders including AL amyloidosis and other monoclonal gammopathy of clinical significance.

Publications

  • Published 1/12/2026

    Fulciniti M, Yao Y, Perini T, Fong Ng J, Schavgoulidze A, Deng S, Cui J, Encinas Mayoral J, Ladisa F, Young RM, Epstein CB, White CM, Ott CJ, Gulla A, Matulis SM, Sperling AS, Morelli E, Boise LH, Binder M, Szalat R, Samur MK, Anderson KC, Munshi NC. ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. Blood Cancer Discov. 2026 Jan 12; 7(1):129-141. PMID: 41104834.

    Read at: PubMed

  • Published 10/14/2025

    Holder EX, Szalat R, Palmer JR, Bertrand KA. Neighborhood disadvantage and multiple myeloma incidence in the Black Women's Health Study. Int J Epidemiol. 2025 Oct 14; 54(6). PMID: 41206638.

    Read at: PubMed

  • Published 9/22/2025

    Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R. Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis-Related Acquired Factor X Deficiency. Am J Hematol. 2025 Dec; 100(12):2416-2420. PMID: 40981270.

    Read at: PubMed

  • Published 9/3/2025

    Ferri GM, Frank A, Li D, Anand P, Abdallah M, Avalone V, Mark Sloan J, Sanchorawala V, Lerner A, Szalat RE, Petrocca F, Edwards CV, Bell BN. When ICAN(S) Becomes ICAN'T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading. Clin Lymphoma Myeloma Leuk. 2026 Jan; 26(1):e77-e82. PMID: 41015712.

    Read at: PubMed

  • Published 3/20/2025

    Battaglini J, Henderson J, Sanchorawala V, Szalat R. Teclistamab therapy for refractory type 1 cryoglobulinemia. Haematologica. 2025 Aug 01; 110(8):1891-1893. PMID: 40109179.

    Read at: PubMed

View All 62 Publications:   View Full Profile in BUMC

Websites

Education

  • Université Paris-Sorbonne, Paris IV, MD
  • Université Paris-Sorbonne, Paris IV, PhD

View all profiles